Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11987622 | 0.94 | IDH1 (0.37) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL11987008 | 0.85 | MAPT (0.48) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL11987002 | 0.83 | NPC1 (0.46) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL11987623 | 0.77 | MAPT (0.36) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL11987648 | 0.77 | IDH1 (0.37) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL11987006 | 0.74 | MAPT (0.58) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL11987645 | 0.67 | NPC1 (0.45) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL197523 | 0.67 | MAPT (1.00) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL26061296 | 0.67 | MAPT (0.71) | MAPTNPC1RAB9AATMSMN1; SMN2 | |
| SCHEMBL14198213 | 0.66 | NPC1 (0.40) | MAPTNPC1RAB9AATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309970-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | UDC IRELAND LTD. (IE) | 2012-12-06 | — | — | US | disclosed |
| US-8247091-B2 | Platinum complex compound and organic electroluminescent device | FUJIFILM CORPORATION (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20110234090-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | FUJIFILM CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309970-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | L1CAM, LIG1, ZC3HAV1L | MAPT 1900/4885NPC1 3900/4885RAB9A 1622/4885 |
| US-20110234090-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | L1CAM, LIG1, ZC3HAV1L | MAPT 1900/4885NPC1 3900/4885RAB9A 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.